1. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial;Goldstein;Lancet,2015
2. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial;Holcomb;JAMA,2015
3. Myles PS, Smith JA, Forbes A, et al. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med. 2017;376:136–148. The authors compared the safety and efficacy of a single high-dose TXA regimen (100 mg/kg prior to cardiopulmonary bypass) in a multicenter randomized controlled trial in patients undergoing coronary artery bypass grafting surgery. There was no difference between TXA (n = 2311) and placebo (n = 2320) in the primary outcomes consisting of death and thromboembolic complications (nonfatal myocardial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction) within 30 days after surgery. Total number of units of blood products was reduced from 7994 with placebo to 4331 with TXA (P < 0.001). In addition, the incidences of major hemorrhage or cardiac tamponade leading to reoperation were reduced by 50% (P = 0.001). Seizures occurred in 0.7% and 0.1% in patients treated with and without TXA, respectively (P = 0.002). TXA seems to be safe and effective in reducing perioperative blood loss in cardiac surgery. However, caution should be exercised for postoperative seizures in some patients receiving high-dose TXA. (Ref. 152).
4. Thromboelastometry-guided intraoperative haemostatic management reduces bleeding and red cell transfusion after paediatric cardiac surgery;Nakayama;Br J Anaesth,2015
5. The incidence and magnitude of fibrinolytic activation in trauma patients;Raza;J Thromb Haemost,2013